Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.43 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903653 | 0.82 | CYP24A1 (0.50) | CYP24A1CYP27A1CYP26A1CYP19A1MAPK1 | |
| SCHEMBL5917029 | 0.82 | CYP24A1 (0.50) | CYP24A1CYP27A1CYP26A1CYP19A1MAPK1 | |
| SCHEMBL5240232 | 0.80 | CYP24A1 (0.44) | EGFRCYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL12698728 | 0.76 | CYP24A1 (0.46) | CYP24A1CYP27A1CYP26A1CYP19A1MAPK1 | |
| SCHEMBL903651 | 0.75 | CYP26A1 (0.54) | CYP24A1CYP27A1CYP26A1CYP19A1ALDH1A1 | |
| SCHEMBL5242273 | 0.74 | EGFR (0.41) | EGFRCYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL9422277 | 0.73 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL6669546 | 0.73 | CYP24A1 (0.53) | CYP24A1CYP27A1CYP26A1CYP19A1 | |
| SCHEMBL31053075 | 0.73 | CYP24A1 (0.62) | CYP24A1CYP27A1CYP26A1CYP19A1ALDH1A1 | |
| SCHEMBL22628601 | 0.73 | CYP24A1 (0.62) | CYP24A1CYP27A1CYP26A1CYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761513-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | Wyeth (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006007503-A1 | TETRACYCLIC COMPOUNDS AS ESTROGEN LIGANDS | WYETH (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004087-A1 | Tetracyclic compounds as estrogen ligands | ESR1, ESRRA, ESR2 | EGFR 30/4885CYP24A1 609/4885CYP27A1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.